Adeel Ahmed-Daudpota
Chief Executive Officer at IMMUNE PHARMACEUTICALS, INC.
Adeel Ahmed-Daudpota active positions
| Companies | Position | Start | End |
|---|---|---|---|
| IMMUNE PHARMACEUTICALS, INC. | Chief Executive Officer | 12/04/2021 | - |
| President | 12/04/2021 | - |
Career history of Adeel Ahmed-Daudpota
Statistics
International
| United States | 2 |
Operational
| Chief Executive Officer | 1 |
| President | 1 |
Sectoral
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 1 |
|---|---|
Immune Pharmaceuticals, Inc.
 Immune Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Its lead product, Bertilimumab, is a human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases. It is also developing NanoCyclo, a topical nano-encapsulated formulation of cyclosporine, for the treatment of atopic dermatitis (AD) and psoriasis. The company was founded by Daniel Gedeon Teper on March 9, 1993 and is headquartered in Englewood Cliffs, NJ. | Health Technology |
- Stock Market
- Insiders
- Adeel Ahmed-Daudpota
- Experience
